EU funding to research project to study the role of systemic endotoxemia as driver of chronic inflammation in arthitis
The EU has awarded a 7 million EUR funding to a HUS Helsinki University Hospital led consortium to study the significance of gut microbiota as a driver of chronic systemic inflammation and the role of microbiota in the pathogenesis of rheumatic diseases. An additional 1.8 million EUR has been granted by the Swiss State Secretariat for Education, Research and Innovation (SERI). The project will start in January 2023. Steinbeis Europa Zentrum supports as project partner the communication and dissemination activities of the consortium, as well as the exploitation of the research results.
Rheumatic diseases (RDs) affect more than 40% of Europe's population and cause significant disability, pain, reduced lifespan, and a very high economic burden. But by now it is unclear, which mechanisms and triggers are responsible for the onset of RDs.
It is suggested that chronic systemic inflammations are caused by the intestinal microorganisms (gut microbiota), or rather by bacterial derived compounds, which activate the immune system. Due to an increased gut permeability, these compounds are able to move from the gut into the blood, reaching systemic circulation and causing local inflammations (systemic endotoxemia).
The EU funded project ENDOTARGET aims to explore the relationship between gut microbiota, gut permeability, and systemic endotoxemia with a special focus on the three most abundant rheumatic diseases (RDs): osteoarthritis, rheumatoid arthritis and spondylarthritis. The events leading to disease onset will be studied by geographically diverse cohorts (blood and feces samples), OMICS-based analyses, clinical studies, in vitro mechanistic studies (tissue cultures, organ on chip models) and proof of concept studies focusing on diet, fecal transplantation, and drugs influencing gut permeability. The aim is to clarify (1) the role of the three factors gut microbiota, gut permeability and systemic endotoxemia in RD onset and pathogenesis, (2) which events and mechanisms are responsible for the origin of RDs, and (3) the influence of the gut microbiota on the joints.
The EU main call objective was to develop a personalized blueprint to reduce chronic inflammation and to prevent health-to-disease transition.
“In this project, we aim to explore the relationship between gut microbiota, intestinal permeability, and systemic endotoxemia. Further we aim to understand their role as drivers of disease onset and disease activity in rheumatoid arthritis, osteoarthritis and spondyloarthritis. The findings of the four-year research consortium may lead to the identification and development of novel preventive and therapeutic approaches,” says ENDOTARGET project leader, Professor Kari Eklund from HUS.
The HUS-led consortium studies will include cohort and register studies, cell molecular functional studies, clinical and diet intervention studies in the rheumatic diseases.
“Moreover, by combining all this data, a machine learning (ML) and AI-informed rheumatic disease prediction tool (RDPT) will be developed for clinicians to help them identify patients with increased risk of developing the target diseases,” concludes Eklund.
The ENDOTARGET-consortium will also empower citizens and patients to be able to manage better their own physical health and well-being by testing a new evidence-based model linking nutrition knowledge, termed “Clinical culinary”, and application of dietary strategies to health promotion and reduction of disease activity of rheumatic diseases.
Apart from HUS, the Consortium consists of several leading European research organizations, such as the University of Helsinki, and research groups from Switzerland, Portugal, Spain, Italy, Austria, and Estonia. The consortium also includes industry partners, specialized in bioinformatics, artificial intelligence, machine learning, and communications. The proposal preparation was supported by company specialized in EU-funding, namely Spinverse.
The ENDOTARGET Consortium: Coordinator HUS Helsinki University Hospital (Finland), University of Helsinki (Finland), University of Tartu, University of Campania “L. Vanvitelli”, University of Lisbon (Portugal), Galician Health Service (SERGAS) (Spain), Technical University of Vienna (Austria), Swiss Federal Institute of Technology (ETH Zurich) (Switzerland), Swiss Institute of Bioinformatics (Switzerland), Biomedical Research Institute of Salerno (Italy), NEC Laboratories Europe GmbH (Germany), Steinbeis 2i GmbH (Germany).
Dr. Lena Schleicher
Steinbeis Europa Zentrum
Professor, Chief Physician Kari Eklund
HUS Helsinki University Hospital
Tel. +358 50 427 0123
Senior Researcher Gonçalo Barreto
HUS Helsinki University Hospital